Nichi-Iko Records Double-digit Growth For 3Q
This article was originally published in PharmAsia News
Executive Summary
Nichi-Iko reported generic drug sales grew by 16.8 percent to ¥46.9 billion for the third quarter ending Aug. 31. Net profit also increased by 2.7 percent to ¥2.7 billion
|
Nichi-Iko reported generic drug sales grew by 16.8 percent to ¥46.9 billion for the third quarter ending Aug. 31. Net profit also increased by 2.7 percent to ¥2.7 billion. The company cited a high market demand as a result of incentives for generic drug prescriptions. Nichi-Iko saw a significant increase in demand for oral generics to treat chronic diseases such as hyperlipidemia. For the fourth quarter, the company revised estimates upward and expected additional sales from a joint venture established this June with Sanofi-Aventis. The generic drug JV has started marketing Amoban (zopiclone) this September for sleeping disorders. (Click here for more - Japanese language) "Nichi-Iko Reports Record Sales And Profits For 3Q"--CB News (10/18/2010) |